Format

Send to

Choose Destination
Cancer Res. 2013 Oct 15;73(20):6359-74. doi: 10.1158/0008-5472.CAN-13-1558-T. Epub 2013 Oct 4.

Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.

Author information

1
Authors' Affiliations: Departments of Surgery, Pathology, and Cell and Developmental Biology, Department of Internal Medicine-Gastroenterology, Michigan Center for Translational Pathology, Program in Cellular and Molecular Biology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan; Vascular Biology Program, Department of Surgery, Karp Family Research Laboratories, Children's Hospital, Boston, Massachusetts; Gastroenterology Division, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Pharmacology, and University of Malaya Cancer Research Institute, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Abstract

Pancreatic cancer, one of the deadliest human malignancies, is almost invariably associated with the presence of an oncogenic form of Kras. Mice expressing oncogenic Kras in the pancreas recapitulate the stepwise progression of the human disease. The inflammatory cytokine interleukin (IL)-6 is often expressed by multiple cell types within the tumor microenvironment. Here, we show that IL-6 is required for the maintenance and progression of pancreatic cancer precursor lesions. In fact, the lack of IL-6 completely ablates cancer progression even in presence of oncogenic Kras. Mechanistically, we show that IL-6 synergizes with oncogenic Kras to activate the reactive oxygen species detoxification program downstream of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling cascade. In addition, IL-6 regulates the inflammatory microenvironment of pancreatic cancer throughout its progression, providing several signals that are essential for carcinogenesis. Thus, IL-6 emerges as a key player at all stages of pancreatic carcinogenesis and a potential therapeutic target.

PMID:
24097820
PMCID:
PMC3831882
DOI:
10.1158/0008-5472.CAN-13-1558-T
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center